An economic evaluation of oxaliplatin for the adjuvant treatment of colon cancer in the United Kingdom (UK)

This publication has 12 references indexed in Scilit:

• Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US
  Cancer, 2007
• Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial
  British Journal of Cancer, 2006
• CN1 COST-EFFECTIVENESS ANALYSIS OF OXALIPLATIN/5-FU/LV IN ADJUVANT TREATMENT OF STAGE III COLON CANCER IN THE UK AND GERMANY
  Value in Health, 2005
• Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
  New England Journal of Medicine, 2004
• Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much?
  Journal of Clinical Oncology, 2004
• Does NICE have a cost‐effectiveness threshold and what other factors influence its decisions? A binary choice analysis
  Health Economics, 2004
• Intensity of chemotherapy-induced emesis and overall survival as determinants of a global utility score
  Supportive Care in Cancer, 2002
• Quality of life in survivors of colorectal carcinoma
  Cancer, 2000
• A Cost-Utility Analysis of Second-Line Chemotherapy in Metastatic Breast Cancer
  PharmacoEconomics, 1996
• A cost utility analysis of treatment options for gallstone disease: Methodological issues and results
  Health Economics, 1994